Vela Diagnostics has launched its Sentosa SQ HCV genotyping assay, which uses next-generation sequencing to genotype hepatitis C virus, to early access customers for research use only. The assay works with plasma or serum and detects genotypes 1, 2, 3, 4, 5, 6, and subtypes 1a and 1b by targeting the NS5A and NS5B regions. It has a limit of detection of 1,000 international units per milliliter for genotypes 1a, 1b, 2, 3, and 4, and 2,000 IU/ml for genotypes 5 and 6. The accuracy rate is 100 percent for HCV genotyping 1a, 1b, 2, 3, 4, 5, and 6 with 99.2 percent reproducibility.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The apple has traveled westward and eastward along the Silk Road, according to a new genetic analysis.

In Nature this week: GWAS data used to reposition drugs for psychiatric use, and more.

Genetic disease risk information doesn't always spur people to make healthy lifestyle changes, according to the Associated Press.

A University of California, San Diego-led team has used liquid biopsies to uncover possible treatments for patients with cancers of unknown primary.

Sep
27
Sponsored by
Philips Genomics

This webinar will present an in-depth look at how Memorial Sloan Kettering Cancer Center has developed and implemented a next-generation sequencing panel for mutational tumor profiling of advanced cancer patients.

Sep
28
Sponsored by
Fabric Genomics

This webinar will discuss the critical role that software can play for clinical labs looking to establish comprehensive genomic testing programs.